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The cry gene family, is a large family of homologous genes from Bacillus 
thuringiensis. Studies have examined the structural and functional 
relationships of the Cry proteins. They have revealed several residues in 
domains II and III that are important for target recognition and receptor 
attachment. In 2007 Wu, Jin-Yu et al employed a maximum likelihood method 
to detect evidence of adaptive evolution in Cry proteins. They identified 
positively selected residues, which are all located in Domain II or III.  Figure 1 
shows a protein sequence alignment between domain II and III of Cry1Ac and 
Cry1Aa. This highlights the areas which are thought to be under positive 
selection. Cry1Ac and Cry1Aa are structurally very similar and they both bind 
to a variety of N-aminopeptidases (APN’s) in different insect species. However 
Cry1Aa has a higher specificity for the cadherin like receptor HevCalP and 
Cry1Ac binds to N-acetylgalactosamine (GalNAc) on the surface of APN’s. 
Differences in the binding of the two toxins has been shown in an in-direct 
toxin-binding assay where GalNAc completely abolished toxin binding of 
Cry1Ac but had no effect on the binding of Cry1Aa. The binding site has been 
shown to be located in the third domain of Cry1Ac. Some of these sites 
correlate with the positively selected residues found by Wu et al 2007 in 
Cry1Aa. Our aim was to use the comparison of the toxins to analyse the 
potential to alter the binding specificity of Cry1Ac and its domains. In this work 
we identified critical amino acid residues for this objective. 
 
1. Predicted protein structure for the recombinant tCry1Ac and CryD3 
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Figure 3: Purification of tCry1Ac (A) and CryD3 (B) 
 
A: 1; Broad range protein ladder, 3; Elution of tCry1Ac 
at 69kDa (lower bands are cleaved protein). B: 1 and 
7; Broad range protein ladder, 2; Cleared lysate, 3; 
Flow through of contaminant proteins, 4; Wash at 
100Mm imidazole, 6 and 7; Elution of CryD3 at 15kDa 
(CryD3 dimer at 30kDa) 
    
2. Purification  of tCry1Ac and CryD3 by IMAC  Conclusions and future work 
 
We have cloned, expressed, and purified 
truncated forms of Cry1Ac, which we 
have shown to be active, binding to 
GalNac and Galactose in ELLA’s. 
Significantly, the recombinant CryD3 has 
a specificity for Galactose rather than 
GalNac. This shows that small 
alterations of Cry1Ac have effects on the 
toxin specificity. Further ELLA’s will be 
carried out on the recombinant tCry1Ac 
and CryD3 to examine the stability of the 
proteins and the specificity if any to the T 
(Gal-beta1,3-GalNAc-alpha1,O-Ser/Thr) 
and Tn (GalNAc-alpha1,O-Ser/Thr) 
antigen and other glycoproteins. Site 
directed mutagenesis is being carried out 
on the predicted binding sites of both 
tCry1Ac and CryD3 to investigate the 
structural basis for binding. 
 
These results show that novel lectins 
with altered binding specificities, that 
may have bio-analytical applications, can 
be formed by the truncation of these 
toxins. 
Figure 4: ELLA showing binding of tCry1ac, CryD3 
and the commercial lectin ECL to neo-
glycoproteins; GalNAc-BSA and Gal,α1-3gal-BSA 
and the glycoprotein Asialofetuin 
 
Significantly tCry1Ac shows binding to GalNac, while 
CryD3 binds to Asialofetunin and α1-3 galactose. This 
result correlates with the predicted binding models from 
I-TASSER.   
Results 
Two truncated forms of Cry1Ac (tCry1Ac and CryD3) have been cloned, expressed in Escherichia coli and purified by Immobilised Metal Affinity Chromatography 
(IMAC) (Figure. 3). The binding abilities of both proteins have been analysed in an Enzyme Linked Lectin Assay (ELLA) (Figure. 4).  
 
3. ELLA of tCry1Ac, CryD3 and ECL  
Figure 2: Expected protein structure models  from I-TASSER 
(protein structure and function predictions)  of  cloned tCry1Ac  
and CryD3.  
 
A. The expected structure of tCry1Ac; the white arrow points to the 
known binding site of GalNAc on the third domain (red). B  shows the 
expected structure of the cloned CryD3  fitting into the Cry1Ac model, 
the white arrow points to the expected binding site of Galactose. C 
shows a more detailed view of  the predicted binding  site of CryD3 
with a salt ion in purple. The 6 X histidine tag is represented in red in 
all pictures.  
Figure 1: Protein sequence alignment of Cry1Ac and Cry1Aa  
This sequence alignment spans the second and third domains of both proteins. 
It shows the amino acids which are positively selected and undergoing  
adaptive evolution represented by yellow arrows. The black arrows indicate the 
amino acids involved in GalNAc binding in Cry1Ac. While the red arrows show 
the amino acids which are positively selected and are predicted to be involved 
in GalNac and Galactose binding according to the protein structure models 
(Figure 2). 
